Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3293-3304

  Gadji, Macoura ^a,c   Awe, Julius Adebayo ^a,d   Rodrigues, Prerana ^a   Kumar, Rajat ^b   Houston, Donald S ^b   Klewes, Ludger ^a   Diéye, Tandakha Ndiaye ^c   Rego, Eduardo Magalhães ^e   Passetto, Roberto Falcão ^e   De Oliveira, Fábio Morato ^e   Mai, Sabine ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d UNIVERSITY OF SKÖVDE   (Sweden)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BONE MARROW; CELL POPULATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMIC INSTABILITY; HUMAN; IMAGE ANALYSIS; KARYOTYPE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; RISK FACTOR; SIDEROBLASTIC ANEMIA; TELOMERE; THREE DIMENSIONAL IMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL NUCLEUS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; TELOMERE; YOUNG ADULT;

EID: 84862509342     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0087     Document Type: Article

References (38)

1. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res 2009;33:1011-6.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
3. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-85.
4. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004;103:3265-70. (Pubitemid 38525649)
5. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76.
6. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-78. (Pubitemid 26173932)
7. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996;20:881-90. (Pubitemid 27042321)
8. Mundle SD, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999;60:36-47. (Pubitemid 28565850)
9. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fasdependent apoptosis. Blood 2002;99:1594-601. (Pubitemid 34533031)
10. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557-63. (Pubitemid 40189051)
11. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010;49:260-9.
12. Gadji M, Vallente R, Klewes L, Righolt C, Wark L, Kongruttanachok N, et al. Nuclear remodeling as a mechanism for genomic instability in cancer. Adv Cancer Res 2011;112:77-126.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
14. Ohyashiki K, Iwama H, Yahata N, Tauchi T, Kawakubo K, Shimamoto T, et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 2001;42:291-9.
15. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-10.
16. Callen E, Surralles J. Telomere dysfunction in genome instability syndromes. Mutat Res 2004;567:85-104. (Pubitemid 39162995)
17. Chuang TC, Moshir S, Garini Y, Chuang AY, Young IT, Vermolen B, et al. The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2004;2:12.
18. Mai S, Garini Y. Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 2005;4:1327-31. (Pubitemid 41437113)
19. Mai S, Garini Y. The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 2006;97:904-15.
20. Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci U S A 2005;102:9613-8. (Pubitemid 40981729)
21. Guffei A, Lichtensztejn Z, Goncalves Dos Santos Silva A, Louis SF, Caporali A, Mai S. c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia 2007;9:578-88. (Pubitemid 47121832)
22. Guijon FB, Greulich-Bode K, Paraskevas M, Baker P, Mai S. Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: possible biomarkers. J Low Genit Tract Dis 2007;11:265-72. (Pubitemid 47530914)
23. Knecht H, Sawan B, Lichtensztejn D, Lemieux B, Wellinger RJ, Mai S. The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 2009;23:565-73.
24. Guffei A, Sarkar R, Klewes L, Righolt C, Knecht H, Mai S. Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles. Haematologica 2010;95:2038-46.
25. Gadji M, Fortin D, Tsanaclis AM, Garini Y, Katzir N, Wienburg Y, et al. Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients. Neoplasia 2010;12:183-91.
26. Drummond MW, Balabanov S, Holyoake TL, Brummendorf TH. Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007;25:1853-61. (Pubitemid 47258163)
27. Boultwood J, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, et al. Telomere length in myelodysplastic syndromes. Am J Hematol 1997;56:266-71. (Pubitemid 127471680)
28. Sashida G, Ohyashiki JH, Nakajima A, Sumi M, Kawakubo K, Tauchi T, et al. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 2003;9:1489-96. (Pubitemid 36418406)
29. Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi S, Shay JW, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999;5:1155-60. (Pubitemid 29233232)
30. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994;54:3557-60. (Pubitemid 24225983)
31. Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC, et al. Characterizing the three-dimensional organization of telomeres. Cytometry A 2005;67:144-50. (Pubitemid 41437531)
32. Schaefer LH, Schuster D, Herz H. Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. J Microsc 2001;204:99-107. (Pubitemid 33064464)
33. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-40.
34. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004;18:2008-14. (Pubitemid 40028428)
35. Raza A, Cruz R, Latif T, Mukherjee S, Galili N. The biology of myelodysplastic syndromes: unity despite heterogeneity. Hematol Rep 2010;2:e4:28-31.
36. Horikawa K, Nakakuma H, Kawaguchi T, Iwamoto N, Nagakura S, Kagimoto T, et al. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 1997;90:2716-22. (Pubitemid 27413481)
37. De Vos WH, Hoebe RA, Joss GH, Haffmans W, Baatout S, Van Oostveldt P, et al. Controlled light exposure microscopy reveals dynamic telomere microterritories throughout the cell cycle. Cytometry A 2009;75:428-39.
38. Lin YW, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005;106:287-95. (Pubitemid 40967204)